ORBi: Detailed Reference

Article (Scientific journals)

Does signalling pathways inhibition hold therapeutic promise for osteoarthritis?

2014 • In Joint Bone Spine, 81, p. 281-283

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/170474

DOI
10.1016/j.jbspin.2014.03.002

PubMed
24709002

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Joint Bone spine Edito BONSOI4004.pdf

Publisher postprint (667.68 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Signalling pathways inhibition hold promise as therapeutic targets in osteoarthritis but safety concern may limit their use to the more sevre form of the disease.

Disciplines :

Rheumatology

Author, co-author :

Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)

Language :

English

Title :

Does signalling pathways inhibition hold therapeutic promise for osteoarthritis?

Publication date :

2014

Journal title :

Joint Bone Spine

ISSN :

1297-319X

eISSN :

1778-7254

Publisher :

Elsevier Science, Paris, France

Volume :

81

Pages :

281-283

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 July 2014

Statistics

Number of views

73 (0 by ULiège)

Number of downloads

240 (0 by ULiège)

More statistics

Scopus citations^®

4

Scopus citations^®
without self-citations

4

OpenCitations

3

OpenAlex citations

3

Article has an altmetric score of 1

See more details

publications

0

supporting

0

mentioning

0

contrasting

0

Smart Citations

0

0

0

0

Citing PublicationsSupportingMentioningContrasting

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Bibliography

Loeser R.F., Goldring S.R., Scanzello C.R., Goldring M.B. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012, 64:1697-1707.
Saito T., Kawaguchi H. HIF-2alpha as a possible therapeutic target of osteoarthritis. Osteoarthritis Cartilage 2010, 18:1552-1556.
Feist E., Burmester G.R. Small molecules targeting JAKs - a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013, 52:1352-1357.
Akasaki Y., Hasegawa A., Saito M., et al. Dysregulated FOXO transcription factors in articular cartilage in aging and osteoarthritis. Osteoarthritis Cartilage 2014, 22:162-170.
Lories R.J., Corr M., Lane N.E. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol 2013, 9:328-339.
Yusuf E., Nelissen R.G., Ioan-Facsinay A., et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis 2010, 69:761-765.
Conde J., Scotece M., Lopez V., et al. Adipokines: novel players in rheumatic diseases. Discov Med 2013, 15:73-83.
Sellam J., Berenbaum F. Is osteoarthritis a metabolic disease?. Joint Bone Spine 2013, 80:568-573.
Puenpatom R.A., Victor T.W. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009, 121:9-20.
Yoshimura N., Muraki S., Oka H., et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis Cartilage 2012, 20:1217-1226.
Zhang W., Nuki G., Moskowitz R.W., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
Chevalier X., Eymard F., Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013, 9:400-410.
Coombs J.H., Bloom B.J., Breedveld F.C., et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010, 69:413-416.
Kremer J.M., Cohen S., Wilkinson B.E., et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012, 64:970-981.
Yano F., Hojo H., Ohba S., et al. A novel disease-modifying osteoarthritis drug candidate targeting Runx1. Ann Rheum Dis 2013, 72:748-753.

Similar publications

Sorry the service is unavailable at the moment. Please try again later.

×

This website uses cookies

This website uses cookies to improve user experience. Read more

Strictly necessary

Performance

Save & Close

Accept all

Decline all

Show details

Cookie declaration

About cookies

Strictly necessary

Performance

Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.

Cookie report
Name	Provider / Domaine	Expiration	Description
JSESSIONID	Oracle Corporation www.uliege.be	Session	General purpose platform session cookie, used by sites written in JSP. Usually used to maintain an anonymous user session by the server.
CookieScriptConsent	CookieScript .uliege.be	1 year	This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.

Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.

Cookie report
Name	Provider / Domaine	Expiration	Description
_pk_id	InnoCraft Ltd .uliege.be	1 year	Used to store a few details about the user such as the unique visitor ID
_pk_ses	InnoCraft Ltd .uliege.be	30 minutes	Short lived cookies used to temporarily store data for the visit
_pk_ref	InnoCraft Ltd .uliege.be	6 months	Used to store the attribution information, the referrer initially used to visit the website

Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.

You can change your consent to cookie usage at any time on our Privacy Policy page.

Cookie report created by CookieScript